Register Login

Akero Therapeutics (AKRO)

  • Event
  • June 16, 2022, 11:14 UTC

(85% Positive) AKERO THERAPEUTICS, INC. (AKRO) Announces Enrollment Update for study Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 7:47 a.m.

    📋 AKERO THERAPEUTICS, INC. (AKRO) - Clinical Trial Update

    Filing Date: 2022-06-16

    Accepted: 2022-06-16 07:14:03

    Event Type: Clinical Trial Update

    Event Details:

    Akero Therapeutics (AKRO) Announces Clinical Trial Update Akero Therapeutics (AKRO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: study, combination
    • Diseases/Conditions: use in Phase 3 clinical trials
    • Clinical Stage: Phase 3, clinical trial
    • Collaboration: NASH
    • Updated Timeline: the third quarter of 2023, the third quarter of 2024

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Akero Therapeutics
    • CIK: 0001744659
    • Ticker Symbol: AKRO
    • Period End Date: 2022-06-15
    • Document Type: 8-K

Search

News categories